The 20 patients who received regular, guidelines-centered therapy followed by targeted, bronchoscope-guided treatment, improved only after beginning targeted therapy. ‘While our study will require additional studies to confirm the findings, it provides a promising step for individuals and doctors who cannot obtain asthma under control, ‘ said Richard Martin, MD, senior author, professor and seat of the National Jewish Wellness Department of Medicine.. Bronchoscopy helps distinguish phenotypes, personalize therapy for refractory asthma Utilizing a bronchoscope to visually examine the airways and collect fluid and tissue can help help effective therapy for difficult-to-treat asthma patients, according to researchers at Nationwide Jewish Wellness. Reporting in the March 2012 problem of the journal Upper body, the researchers identified five distinct phenotypes among the refractory asthma sufferers, and treated four of them successfully, with minimal asthma medications often.Fifty % were selected to get either the mix of cetuximab with chemotherapy or chemotherapy only. Individuals getting the cetuximab with chemotherapy mixture lived, typically, 10.1 months compared with 7.4 months for those receiving chemotherapy only. The most typical side effects reported in sufferers receiving cetuximab were rash, itching , nail changes, headache, diarrhea, and respiratory, epidermis, and mouth infections. Erbitux can also trigger low serum magnesium, potassium, and calcium. Erbitux has been connected with serious and life-threatening infusion reactions and coronary attack potentially. Patients acquiring Erbitux should limit their contact with the sun. Erbitux was first accepted by the FDA in 2004 to take care of Epidermal Growth Factor Receptor -positive late-stage cancer of the colon after patients stopped responding to chemotherapy.